Getting an injection in the eye is unlikely to appear on anyone’s list of relaxing afternoon activities. Still, intravitreal medicines such as Beovu can play an important role in protecting vision. Beovu, whose active ingredient is brolucizumab-dbll, is an anti-VEGF medication approved for adults with neovascular, or “wet,” age-related macular degeneration and diabetic macular edema. It works by blocking vascular endothelial growth factor, a protein that encourages abnormal blood vessels to grow and leak inside the eye.

Like every prescription treatment, Beovu has possible side effects. Some are mild and temporary, including irritation, a small blood spot on the eye, or short-lived blurry vision. Others require immediate attention because they may threaten vision. The most important warnings involve inflammation inside the eye, retinal vasculitis, blocked retinal blood vessels, infection, retinal detachment, and increased eye pressure.

Medical note: This article provides general education and cannot determine whether a symptom is harmless. After a Beovu injection, contact your ophthalmologist promptly about new pain, worsening redness, light sensitivity, increasing floaters, or any change in vision.

What are the most common Beovu side effects?

The current U.S. prescribing information lists blurred vision, cataract, conjunctival hemorrhage, vitreous floaters, and eye pain among the most frequently reported adverse reactions. The percentages differed between people treated for wet AMD and those treated for diabetic macular edema. Clinical-trial percentages are useful guides, but they cannot predict exactly what will happen to an individual patient.

These figures include events reported during treatment and do not always prove that Beovu directly caused the problem. Eye conditions such as wet AMD and diabetic macular edema can themselves affect vision, while the injection procedure has its own potential effects. In other words, the eye is a complicated neighborhood, and not every unusual visitor arrived in Beovu’s car.

Common and potentially mild Beovu side effects

Temporary blurry vision

Vision may be blurry immediately after an intravitreal injection because of the medication, numbing agents, antiseptic solution, dilating drops, the eye examination, or a temporary change in pressure. Patients should not drive or operate machinery until their vision has returned to its usual level.

Brief blurring that steadily improves may be expected. Blurring that becomes worse, appears suddenly after initially improving, or occurs with pain, redness, floaters, or light sensitivity needs urgent evaluation. A serious problem can begin with a symptom that initially sounds ordinary.

A small red patch on the white of the eye

A conjunctival hemorrhage is a small amount of bleeding beneath the transparent surface covering the white part of the eye. It can look impressively dramaticrather like the eye volunteered for a horror moviebut it is often painless. It commonly results from a tiny surface blood vessel being disturbed during the injection.

The patch may spread or change color while healing. However, bleeding accompanied by worsening vision, significant pain, swelling, or bleeding inside the field of vision should not be treated as a routine red spot. Call the eye clinic for guidance.

Mild irritation or a scratchy feeling

The antiseptic used to clean the eye may cause temporary burning, watering, dryness, or a gritty sensation. The National Eye Institute notes that short-term irritation after an eye injection may clear within a day or two. Preservative-free artificial tears may be helpful when approved by the treating clinician, but patients should not rub the eye or use unapproved drops.

Floaters or bubbles

Some people temporarily see a bubble or small moving spots after an intravitreal injection. A stable bubble that gradually disappears may be related to the procedure. Nevertheless, new floaters can also occur with inflammation, bleeding, a retinal tear, or retinal detachment. A sudden shower of specks, flashes of light, a curtain-like shadow, or reduced vision warrants immediate contact with an ophthalmologist.

Eye discomfort

Mild pressure or soreness can occur after the injection. Severe pain is not something to “sleep off and see how it looks next Tuesday.” Pain that is increasing, persistent, or accompanied by redness, discharge, light sensitivity, nausea, or vision loss may indicate infection, inflammation, or high eye pressure.

Cataract or vitreous detachment

Cataract and vitreous detachment were reported during Beovu trials, particularly in the wet AMD population. These conditions are also more common with aging and may develop independently of treatment. Cataracts usually cause gradual clouding, glare, or faded colors. Vitreous detachment can cause floaters and flashes and occasionally creates a retinal tear. An eye examination is needed to determine the cause rather than blaming every visual squiggle on the latest injection.

Serious Beovu side effects

Intraocular inflammation

Intraocular inflammation means inflammation within the eye. The FDA label groups several diagnoses under this term, including iritis, uveitis, vitritis, retinal vasculitis, and retinal vascular occlusion. Warning signs may include worsening redness, eye pain, blurred or reduced vision, light sensitivity, and increasing floaters.

Beovu should not be administered when active intraocular inflammation is present. Patients who develop inflammation during treatment require close monitoring because inflammation may be associated with retinal vasculitis or vascular blockage. Research reviews and postmarketing reports have reinforced the importance of recognizing these events promptly.

Retinal vasculitis and retinal vascular occlusion

Retinal vasculitis is inflammation of blood vessels in the retina. Retinal vascular occlusion occurs when blood flow through a retinal vessel becomes blocked. These immune-mediated adverse events have usually been reported alongside intraocular inflammation, although their presentation can vary. They may happen after the first Beovu injection, not only after months of treatment.

These complications can cause permanent vision loss. The prescribing information instructs clinicians to discontinue Beovu in patients who develop retinal vasculitis or retinal vascular occlusion. Any sudden dimming, missing area, unusual haze, reduced color perception, or other visual change deserves immediate assessment rather than an appointment several weeks later.

Endophthalmitis

Endophthalmitis is a serious infection inside the eye and is a potential complication of intravitreal injections in general. Symptoms may include worsening eye pain, increasing redness, swollen eyelids, light sensitivity, discharge, floaters, or reduced vision. It requires urgent treatment to reduce the risk of severe vision damage. Sterile injection techniques reduce risk but cannot make it zero.

Retinal tear or retinal detachment

A retinal detachment occurs when the retina separates from its normal position. Warning signs include flashes, many new floaters, a dark curtain or shadow, and sudden loss of part of the visual field. Retinal detachment is an emergency because delaying treatment increases the chance of permanent vision loss.

Increased pressure inside the eye

Eye pressure can rise acutely within 30 minutes of a Beovu injection, and sustained increases have also been reported. The clinician should monitor intraocular pressure and blood flow at the optic nerve after treatment. Severe pain, headache, halos around lights, nausea, vomiting, or abruptly worse vision should be reported urgently.

Arterial thromboembolic events

Anti-VEGF medicines carry a potential risk of arterial thromboembolic events, such as nonfatal stroke, nonfatal heart attack, or vascular death. In the two 96-week wet AMD trials, these events occurred in 4.5% of patients in the pooled brolucizumab groups and 4.7% of patients receiving aflibercept. The similar trial percentages do not eliminate the broader class warning.

Call emergency services for chest pressure, trouble breathing, sudden weakness or numbness on one side, facial drooping, confusion, difficulty speaking, or a sudden severe headache. These symptoms should be treated as emergencies regardless of whether a recent eye injection is responsible.

Allergic or hypersensitivity reactions

Hypersensitivity may cause rash, itching, hives, skin redness, swelling, or severe inflammation inside the eye. Beovu is contraindicated in people with known hypersensitivity to brolucizumab or its ingredients. Trouble breathing, facial or throat swelling, faintness, or a rapidly progressing reaction requires emergency medical care.

When should you call your eye doctor?

Contact the treating ophthalmologist immediately after a Beovu injection if you develop any of the following:

• New or worsening vision loss
• Increasing eye pain rather than mild soreness that improves
• Worsening redness or swelling
• New sensitivity to light
• A sudden increase in floaters or flashes
• A dark curtain, shadow, or missing portion of vision
• Discharge from the eye
• Severe headache, nausea, or halos around lights
• Rash, hives, itching, or swelling

Do not wait for a routine follow-up when vision is changing. The FDA-approved patient counseling information specifically advises patients to report redness, pain, light sensitivity, blurring, and other vision changes without delay.

Who should not receive Beovu?

Beovu is contraindicated in patients who have an infection in or around the eye, active inflammation inside the eye, or known hypersensitivity to brolucizumab or the product’s ingredients. Tell the ophthalmologist about recent eye inflammation, surgery, infection, stroke, heart attack, glaucoma, pressure problems, allergies, and all prescription medicines, over-the-counter products, vitamins, and supplements.

People who are pregnant, planning pregnancy, or breastfeeding should discuss their situation before treatment. The prescribing information states that Beovu may pose a risk to embryo-fetal development based on its anti-VEGF mechanism. Effective contraception is recommended during treatment and for one month after the final dose, and breastfeeding is not recommended during that period.

How can the risk of complications be reduced?

The injection must be administered by a qualified eye specialist using sterile technique. Patients should keep scheduled examinations, follow the personalized dosing plan, and report symptoms promptly. During maintenance therapy, the U.S. label states that the interval between Beovu doses should not be shorter than eight weeks. A study using four-week maintenance dosing found a higher incidence of intraocular inflammation and retinal vascular occlusion than the eight- or 12-week schedules used in earlier trials.

Before leaving the clinic, make sure you know which number to call after hours. Consider arranging transportation because temporary visual disturbance can make driving unsafe. Ask whether artificial tears are appropriate, when you may resume exercise, and whether you should avoid swimming, eye makeup, or rubbing the treated eye.

How long do Beovu side effects last?

Minor irritation or a temporary bubble may improve within a day or two. A small surface blood spot can remain visible longer while the blood is reabsorbed. Dilating drops and temporary blurring may last several hours. Cataract, retinal disease, inflammation, infection, or pressure-related complications do not follow a simple home-treatment timeline and require professional assessment.

A useful rule is to focus on direction. Mild symptoms should generally remain stable or improve. Symptoms that intensify, return after improving, or are joined by new visual changes deserve a call. The eye is not a great place for heroic waiting.

Experiences and practical lessons from Beovu treatment

The following scenarios are composites based on common post-injection concerns. They are not quotations from specific patients and should not be used to diagnose a personal symptom.

Experience 1: The alarming red spot

A patient looks in the mirror several hours after an injection and notices a bright red patch on the white of the treated eye. There is no meaningful pain, vision is returning to baseline, and the patch is outside the colored portion of the eye. The clinic explains that a small conjunctival hemorrhage can occur when a surface blood vessel is disturbed.

The practical lesson is that appearance and seriousness do not always travel together. A harmless surface spot can look spectacular, while a dangerous problem inside the eye may not be visible in the mirror. The patient still follows the clinic’s instructions and watches for pain, swelling, light sensitivity, or worsening vision instead of relying on appearance alone.

Experience 2: The floating bubble

Another patient sees a dark circle that moves when the eye moves. It appeared immediately after the procedure and gradually becomes smaller. The clinic had mentioned that a temporary air bubble could look like a floater. Because the symptom is improving and there are no flashes, shadows, pain, or vision loss, the patient continues monitoring it.

Later, the patient receives a different injection and notices a sudden shower of tiny spots with flashes at the edge of vision. Remembering that not every floater is equal, the patient calls immediately. A same-day retinal examination is arranged. The experience illustrates why post-injection instructions should describe patterns, not merely list the word “floaters.” One familiar dot that steadily disappears is different from dozens of new specks accompanied by flashes or a curtain-like shadow.

Experience 3: Symptoms that begin days later

A third patient feels reasonably comfortable after the injection but develops increasing light sensitivity, redness, and hazy vision several days later. Because the injection was not recent enough to feel “immediate,” the patient is tempted to wait for the next scheduled appointment.

Instead, the patient calls the retinal specialist. That decision matters because Beovu-associated inflammation, retinal vasculitis, vascular occlusion, and infection may not announce themselves before the patient leaves the clinic. Serious immune-mediated events can also occur after the first injection. The absence of a problem during the initial pressure check does not guarantee that no later complication will occur.

Experience 4: Preparing before the appointment

Some of the least glamorous preparation creates the greatest peace of mind. One patient saves the clinic’s daytime and after-hours numbers, arranges a ride, brings sunglasses for light sensitivity, and asks what symptoms justify an emergency visit. The patient also writes down baseline vision problems before the injection. That makes it easier to identify what is truly new afterward.

The patient does not plan to judge safety by pain alone. Retinal vascular problems can present primarily as a change in vision, while antiseptic irritation can sting without indicating a sight-threatening complication. Having written instructions reduces the chance that uncertainty becomes either panic over every blink or dangerous delay.

What these experiences teach

Most post-injection questions fall into three categories: symptoms that are mild and improving, symptoms that are unfamiliar but stable, and symptoms that are worsening or affecting vision. The first group may be monitored according to the clinician’s instructions. The second deserves a telephone call when there is uncertainty. The third should be treated as urgent.

Patients should never feel embarrassed about calling the eye clinic. Retinal specialists would generally rather evaluate a false alarm than learn that a patient waited through progressive vision loss. Asking questions is not being difficult; it is participating in the treatment plan.

Conclusion

Common Beovu side effects include blurred vision, a surface blood spot, floaters, eye discomfort, cataract, and temporary changes in eye pressure. Some post-injection irritation may improve quickly, but symptoms cannot be classified safely by name alone. New floaters, for example, may represent a temporary bubble or a retinal emergency depending on their pattern and accompanying symptoms.

The most serious Beovu risks include intraocular inflammation, retinal vasculitis, retinal vascular occlusion, endophthalmitis, retinal detachment, increased eye pressure, hypersensitivity, and possible arterial thromboembolic events. Prompt evaluation is essential when pain, redness, light sensitivity, flashes, numerous floaters, shadows, or vision loss develops. Patients should follow their ophthalmologist’s dosing and monitoring plan rather than stopping or delaying treatment independently.

Note: Medical guidance and product labeling may change. This content should be reviewed periodically against the latest U.S. prescribing information and should not replace advice from an ophthalmologist.